HD, sorry if this has already been asked of you. Do you have an opinion as to whether the UK will approve some sort of reimbursement for Vazkepa or deny it completely? TIA
Not sure why you're so fixated on Sweden . Its a relatively small market ( 10.4 million ) compared to Germany ..over 83 million .( total populations ) Economic headwinds
Last I looked Sweden was expecting to still grow by 3% this year . The new WAC to be agreed on this year between Germany and AMRIN will IMHO be significantly lower than what AMRN currently receives ...so how does that not affect margins for at least that market ...the largest in the EU
AMRN appears to be increasing rebates in the US which will also lower margins . Re formularies ...I'll defer to poster Duke on those as he's spent more time navigating them then I ever want to.
U raised an important pt regarding AMRN purchasing contracts. They can keep this to the minimum , thus work off inventory and reduce cash burn